Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 4/20 | 0.55 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864745 | 0.90 | MAPT (0.57) | SCN1ASCN8ASIGMAR1MAPTPKM | |
| SCHEMBL5865016 | 0.85 | SCN8A (0.49) | SCN1ASCN8AKCNH2MAPTRAB9A | |
| SCHEMBL5864901 | 0.83 | MAPT (0.46) | MAPTMAPK1RAB9A | |
| SCHEMBL28772306 | 0.82 | HTR2A (0.63) | HTR2ASIGMAR1KCNJ1KCNH2HRH3 | |
| SCHEMBL5865001 | 0.81 | SCD (0.53) | MAPTMAPK1RAB9A | |
| SCHEMBL5864786 | 0.81 | SCN1A (0.55) | SCN1ASCN8AHTR2ASIGMAR1ACHE | |
| SCHEMBL3979711 | 0.81 | SCD (0.51) | MAPTMAPK1RAB9AACHE | |
| SCHEMBL5865032 | 0.80 | SCN8A (0.59) | SCN1ASCN8ASIGMAR1MAPTPKM | |
| SCHEMBL20694189 | 0.79 | ALDH1A1 (0.57) | MAPTMAPK1RAB9A | |
| SCHEMBL27265100 | 0.79 | HSD17B10 (0.53) | MAPTPKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | SCN1A 572/4885SCN8A 763/4885HTR2A 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.